Results 141 to 150 of about 3,775 (204)

Fidaxomicin Treatment of Clostridioides difficile Infections and Recurrences in Children and Adolescents: A Retrospective Multicenter Study. [PDF]

J Pediatr
Conrad MA, Kaplan AL, Weinbrom S, Nastasio S, Jo D, Conover K, Lo K, Liu E, Crawford M, Michail S, Nicholson M, Hourigan SK, Kelsen JR, Kahn SA.   +13 more
europepmc   +1 more source

Multiple episodes of paediatric <i>Clostridioides difficile</i> infection (pCDI) in the context of autoimmune polyendocrine syndrome type 1. [PDF]

BMJ Case Rep
Kirr HM, Lütke A, Klafke N.
europepmc   +1 more source

Clinician Management Preferences for <i>Clostridioides difficile</i> Infection in Adults: A 2024 Emerging Infections Network Survey. [PDF]

Open Forum Infect Dis
Boton N, Patel PK, Beekmann SE, Polgreen PM, Buckel WR, Mahoney MV, Mehrotra P, Lee MSL.   +7 more
europepmc   +1 more source

Recurrent Clostridium difficile Infections in a Patient With Ulcerative Colitis: A Case Report. [PDF]

Cureus
Nadeem O, Imran MS, Siddique N.
europepmc   +1 more source

Bezlotoxumab for prevention of <i>Clostridioides difficile</i> recurrence in patients with inflammatory bowel disease: a retrospective multicenter experience. [PDF]

Ann Gastroenterol
Karime C, Odah T, Hashash JG, Pardi DS, Khanna S, Farraye FA.   +5 more
europepmc   +1 more source

Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study. [PDF]

J Crohns Colitis
europepmc   +1 more source

Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition. [PDF]

Gastroenterology
Irwin S, van Daelen M, Almaraz I, Park R, Nelson B, Mahurkar-Joshi S, Rieder F, Shih DQ, Ho W, Limketkai B, Koon HW.   +10 more
europepmc   +1 more source